PMCB PharmaCyte Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1157075 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,334.7%
TTM EPS YoY-3,566.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.4%
ROA-39.5%
ROIC (approx.)-27.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.8%
Debt / equity0.00x
Current ratio40.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 | FY20242024-04-30 | FY20232023-04-30 | FY20222022-04-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $391,301 | $438,416 | $407,431 | $468,536 | $690,937 |
| SG&A expense | $4.91M | $3.94M | $6.11M | $1.11M | $1.09M |
| Operating income | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M |
| Interest expense | — | — | — | $0 | $509 |
| Pretax income | -$19.42M | $30.66M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.42M | $30.66M | $333,763 | -$4.32M | -$4.24M |
| EPS (basic) | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 |
| EPS (diluted) | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 |
| Weighted avg. shares (diluted) | 8.38M | 7.33M | 9.58M | 19.49M | 15.52M |
| Balance sheet | |||||
| Cash & equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M |
| Short-term investments | $254,010 | $366,316 | $0 | — | — |
| Current assets | $37.42M | $22.38M | $50.44M | $68.15M | $85.49M |
| Intangibles | $0 | $1.55M | $1.55M | $3.55M | $3.55M |
| Total assets | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M |
| Current liabilities | $826,424 | $2.91M | $7.42M | $586,581 | $704,370 |
| Total liabilities | $11.77M | $3.28M | $20.39M | $586,581 | $704,370 |
| Shareholders' equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M |
| Shares outstanding | 10.74M | 6.80M | 8.04M | 16.79M | 20.72M |
| Cash flow statement | |||||
| Operating cash flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M |
| Investing cash flow | $2.00M | -$7.00M | -$5.00M | $0 | $0 |
| Financing cash flow | $6.58M | -$25.03M | -$10.71M | -$13.56M | $87.31M |
| Stock-based compensation | $892,500 | $0 | $674,693 | $7,334 | $33,146 |
| Share buybacks | $401,625 | $2.54M | $28.20M | $13.56M | $0 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.